Erratum to “The association between pentraxin 3 and insulin resistance in obese children at baseline and after physical activity intervention” [Clin. Chim. Acta 413 (2012) 1430–1437] (S000989811200304X) (10.1016/j.cca.2012.06.002));The association between pentraxin 3 and insulin resistance in obese children at baseline and after physical activity intervention

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1430-1437

  Chu, Sang Hui ^a   Park, Ji Hye ^a   Lee, Mi Kyung ^a   Jekal, Yoonsuk ^a   Ahn, Ki Yong ^a   Chung, Jae Youn ^a   Lee, Dong Hoon ^a   Kim, Eun Sung ^a   Naruse, Masayo ^a   Im, Jee Aee ^e   Kong, Deok ^b   Chung, Choon Hee ^b   Lee, Ji Won ^c   Chung, Kyong Mee ^a   Kim, Young Bum ^d   Jeon, Justin Y ^a  

^a Yonsei University   (South Korea)

^b Yonsei University Wonju College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d HARVARD MEDICAL SCHOOL   (United States)

^e INTOTO Inc   (South Korea)

Author keywords

Exercise; HOMA IR; Obesity; Physical activity; PTX3

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PENTRAXIN 3; TRIACYLGLYCEROL;

ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CHILD; CHILDHOOD OBESITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERVENTION STUDY; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PUBERTY; SCHOOL CHILD; SCORING SYSTEM; SUBCUTANEOUS FAT; TANNER STAGE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 84862610986     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.06.029     Document Type: Erratum

References (40)

1. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295:1549-1555.
2. Sinha R., Fisch G., Teague B., et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002, 346:802-810.
3. Cai D., Yuan M., Frantz D.F., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11:183-190.
4. Alikasifoglu A., Gonc E.N., Ozon Z.A., et al. The relationship between serum adiponectin, tumor necrosis factor-alpha, leptin levels and insulin sensitivity in childhood and adolescent obesity: adiponectin is a marker of metabolic syndrome. J Clin Res Pediatr Endocrinol 2009, 1:233-239.
5. Goldfine A.B., Fonseca V., Shoelson S.E. Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem 2011, 57:162-167.
6. Kim E.S., Im J.A., Kim K.C., et al. Improved insulin sensitivity and adiponectin level after exercise training in obese Korean youth. Obesity 2007, 15:3023-3030.
7. Garlanda C., Bottazzi B., Bastone A., et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005, 23:337-366.
8. Cotena A., Maina V., Sironi M., et al. Complement dependent amplification of the innate response to a cognate microbial ligand by the long pentraxin PTX3. J Immunol 2007, 179:6311-6317.
9. Castell J.V., Gomez-Lechon M.J., David M., et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990, 12:1179-1186.
10. Abderrahim-Ferkoune A., Bezy O., Chiellini C., et al. Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells. J Lipid Res 2003, 44:994-1000.
11. Klouche M., Peri G., Knabbe C., et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 2004, 175:221-228.
12. Introna M., Alles V.V., Castellano M., et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 1996, 87:1862-1872.
13. Norata G.D., Marchesi P., Pulakazhi Venu V.K., et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009, 120:699-708.
14. Zanetti M., Bosutti A., Ferreira C., et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med 2009, 9:243-248.
15. Suzuki S., Takeishi Y., Niizeki T., et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008, 155:75-81.
16. Kasai T., Inoue K., Kumagai T., et al. Plasma pentraxin3 and arterial stiffness in men with obstructive sleep apnea. Am J Hypertens 2011, 24:401-407.
17. Hollan I., Bottazzi B., Cuccovillo I., et al. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res (Hoboken) 2010, 62:378-385.
18. Balagopal P., George D., Patton N., et al. Lifestyle-only intervention attenuates the inflammatory state associated with obesity: a randomized controlled study in adolescents. J Pediatr 2005, 146:342-348.
19. Bradley R.L., Jeon J.Y., Liu F.F., et al. Voluntary exercise improves insulin sensitivity and adipose tissue inflammation in diet-induced obese mice. Am J Physiol Endocrinol Metab 2008, 295:E586-E594.
20. Fukuda T., Kurano M., Iida H., et al. Cardiac rehabilitation decreases plasma pentraxin 3 in patients with cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2011.
21. Nakajima T., Kurano M., Hasegawa T., et al. Pentraxin3 and high-sensitive C-reactive protein are independent inflammatory markers released during high-intensity exercise. Eur J Appl Physiol 2010, 110:905-913.
22. Lee M.K., Jekal Y., Im J.A., et al. Reduced serum vaspin concentrations in obese children following short-term intensive lifestyle modification. Clin Chim Acta 2010, 411:381-385.
23. Marshall W.A., Tanner J.M. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970, 45:13-23.
24. Levy-Marchal C., Arslanian S., Cutfield W., et al. Insulin resistance in children: consensus, perspective, and future directions. J Clin Endocrinol Metab 2010, 95:5189-5198.
25. Moran A., Jacobs D.R., Steinberger J., et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 1999, 48:2039-2044.
26. McAuley K.A., Mann J.I., Chase J.G., et al. Point: HOMA-satisfactory for the time being: HOMA: the best bet for the simple determination of insulin sensitivity, until something better comes along. Diabetes Care 2007, 30:2411-2413.
27. Schwartz B., Jacobs D.R., Moran A., et al. Measurement of insulin sensitivity in children: comparison between the euglycemic-hyperinsulinemic clamp and surrogate measures. Diabetes Care 2008, 31:783-788.
28. Rolph M.S., Zimmer S., Bottazzi B., et al. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002, 22:e10-e14.
29. Peri G., Introna M., Corradi D., et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000, 102:636-641.
30. Suliman M.E., Yilmaz M.I., Carrero J.J., et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008, 3:976-985.
31. Jylhava J., Haarala A., Kahonen M., et al. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol 2011, 164:211-217.
32. Ogawa T., Kawano Y., Imamura T., et al. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity (Silver Spring) 2010, 18:1871-1874.
33. Yamasaki K., Kurimura M., Kasai T., et al. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 2009, 47:471-477.
34. Miyaki A., Maeda S., Otsuki T., et al. Plasma pentraxin 3 concentration increases in endurance-trained men. Med Sci Sports Exerc 2011, 43:12-17.
35. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010, 72:219-246.
36. Nauta A.J., Bottazzi B., Mantovani A., et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 2003, 33:465-473.
37. Sowers J.R. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004, 286:H1597-H1602.
38. Norata G.D., Marchesi P., Pirillo A., et al. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 2008, 28:925-931.
39. Conles O.O., Guitart M., Chacon M.R., et al. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, while visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab 2011, 30:E1254-E1261.
40. Shim B.J., Jeon H.K., Lee S.J., et al. The relationship between serum pentraxin 3 and central obesity in ST-segment elevation myocardial infarction patients. Korean Circ J 2010, 40:308-313.